• 1
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:122336.
  • 2
    Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: DunaifA, GivensJR, HaseltineF, editors. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992. p. 37784.
  • 3
    The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:417.
  • 4
    Pasquali R, Gambineri A. PCOS: a multifaceted disease from adolescence to adult age. Ann NY Acad Sci 2006 (in press).
  • 5
    Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Rel Metab Disord 2002;26:88396.
  • 6
    Haslan DW, James WPT. Obesity . Lancet 2005;366:1197209.
  • 7
    Ford ES. Prevalence of the metabolic syndrome in US population. Endocrinol Metab Clin North Am 2004;33:33350.
  • 8
    Linnè Y. Effects of obesity on women’s reproduction and complications during pregnancy. Obes Rev 2004;5:13743.
  • 9
    Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 2003;9:35972.
  • 10
    Azziz JR, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:45362.
  • 11
    World Health Organization. Obesity. Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. WHO/NUT/NCD 98.1. Geneva, Switzerland: World Health Organization; 1997.
  • 12
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774800.
  • 13
    Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:53582.
  • 14
    Von Shoultz B, Calstrom K. On the regulation of sex-hormone-binding globulin. A challenge of old dogma and outlines of an alternative mechanism. J Steroid Biochem 1989;32:32734.
  • 15
    Pasquali R, Vicennati V, Pagotto U. Endocrine determinants of fat distribution. In: BrayGA, BouchardC, editors. Handbook of Obesity. New York: M. Dekker, Inc, 2003. p. 67192.
  • 16
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697738.
  • 17
    Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990;70:4739.
  • 18
    Kurtz BR, Givens JR, Koinindir S, Stevens MD, Karas JG, Bittle JB, et al. Maintenance of normal circulating levels of Δ4-androstenedione and dehydroepiandrosterone in simple obesity despite increased metabolic clearance rate: evidence for a servo-control mechanism. J Clin Endocrinol Metab 1987;64:12617.
  • 19
    Azziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 1989;52:70325.
  • 20
    Pasquali R. Obesity and androgens: fact and perspectives. Fertil Steril 2006;85:131940.
  • 21
    Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997;350:11315.
  • 22
    Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome—a hypothesis. J Endocrinol 2002;174:15.
  • 23
    Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000;85:120610.
  • 24
    Robinson JE, Forsdike RA, Taylor JA. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 1999;140:5797805.
  • 25
    Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity. Reproduction 2005;130:58397.
  • 26
    Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:2925.
  • 27
    Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: a review. Fertil Steril 2002;77:43344.
  • 28
    Agarwal SK, Vogel K, Weitsman SR, Magoffin DA. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab 1999;84:10726.
  • 29
    Duggal PS, Van Der Hoek KH, Milner CR, Ryan NK, Armstrong DT, Magoffin DA, et al. The in vivo and in vitro effects of exogenous leptin on ovulation in rat. Endocrinology 2000;141:19716.
  • 30
    Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73100.
  • 31
    Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:8390.
  • 32
    Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:8997.
  • 33
    Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:87384.
  • 34
    Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:5218.
  • 35
    Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:77184.
  • 36
    Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:42331.
  • 37
    Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003;27:289301.
  • 38
    Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:15679.
  • 39
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:138997.
  • 40
    Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:212134.
  • 41
    Gammon CM, Freeman M Jr, Xie W, Petersen S, Wetsel WC. Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology 2005;146:44919.
  • 42
    Murphy LL, Steger RW, Smith MS, Bartke A. Effects of D9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 1990;52:31621.
  • 43
    Smith CG, Smith MT, Besch NF, Smith RG, Asch RH. Effect of D9-tetrahydrocannabinol (THC) on female reproductive function. Adv Biosci 1978;22–23:44967.
  • 44
    Smith CG, Almirez RG, Berenberg J, Asch RH. Tolerance develops to the disruptive effects of D9-tetrahydrocannabinol on primate menstrual cycle. Science 1983;219:14535.
  • 45
    Murphy LL, Munoz RM, Adrian BA, Villanua MA. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998;5:43246.
  • 46
    Stella N. How might cannabinoids influence sexual behavior? Proc Natl Acad Sci USA 2001;98:7935.
  • 47
    Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, et al. N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids 2002;121:21127.
  • 48
    Treinen KA, Sneeden JL, Heindel JJ. Specific inhibition of FSH-stimulated cAMP accumulation by D9-tetrahydrocannabinol in cultured rat granulosa cells. Toxicol Appl Pharmacol 1993;118:537.
  • 49
    Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000;355:13269.
  • 50
    Maccarrone M, Finazzi-Agro A. Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 2004;25:3537.
  • 51
    Rossato M, Ion Popa F, Ferigo M, Clari G, Foresta C. Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab 2005;90:98491.
  • 52
    Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Phenotype and associated factors. Diabetes 2004;53:23538.
  • 53
    Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:9427.
  • 54
    Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:51727.
  • 55
    Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:248697.
  • 56
    Pasquali R, Patton L, Pagotto U, Gambineri A. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. Minerva Ginecol 2005;57:7985.
  • 57
    Galtier-Dereure F, Pujol P, Dewailly D, Bringer J. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum Reprod 1997;12:8896.
  • 58
    Lobo RA, Gysler M, March CM, Goebelman U, Mischell Dr Jr. Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982;37:16874.
  • 59
    De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:6337.
  • 60
    Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;25:187680.
  • 61
    Filicori M, Flamigni C, Dellai P. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994;79:121520.
  • 62
    White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996;81:38214.
  • 63
    Fedorcsák P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:108691.
  • 64
    Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;16:125560.
  • 65
    Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata Y. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 1995;86:51619.
  • 66
    Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:258693.
  • 67
    Segal KR, Dunaif A. Resting metabolic rate and postprandial thermogenesis in polycystic ovary syndrome. Int J Obes Relat Metab Disord 1990;14:55967.
  • 68
    Jaatinen T-A, Anttila L, Erkkola R, Koskinen P, Laippala P, Ruutiainen K, et al. Hormonal responses to physical exercise in patients with polycystic ovarian syndrome. Fertil Steril 1993;60:2627.
  • 69
    Pasquali R, Gambineri A. Treatment of the polycystic ovary syndrome with lifestyle intervention. Curr Opin Endocrinol Metab 2002;9:45968.
  • 70
    Richter EA, Mikines KJ, Galbo H, Kiens B. Effect of exercise on insulin action in human skeletal muscle. J Appl Physiol 1989;66:E87685.
  • 71
    Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol 2001;254:E24859.
  • 72
    Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev 2001;6:27292.
  • 73
    Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:4219.
  • 74
    Gambineri A, Pelusi C, Genghini S, Morselli-Labate, AM, Cacciari M, Pagotto U, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:2419.
  • 75
    Harlass FE, Plymate SR, Fariss BL, Belts RP. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984;42:64952.
  • 76
    Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:61116.
  • 77
    Jakubowicz DA, Nestler JE. 17a-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after weight loss. J Clin Endocrinol Metab 1997;82:55660.
  • 78
    Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;81:6307.
  • 79
    Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:81219.
  • 80
    Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:1739.
  • 81
    Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic anovulatory women. Fertil Steril 1994;61:598604.
  • 82
    Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996;11:188491.
  • 83
    Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:270512.
  • 84
    Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:10511.
  • 85
    Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299306.
  • 86
    Ehrmann DA. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:42338.
  • 87
    Kim LH, Taylor AE, Barbieri RL. Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril 2000;73:10978.
  • 88
    Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:9513.
  • 89
    Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:247483.
  • 90
    Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:192832.